Morocco recalls two Cardioaspirine 100 mg batches after temperature deviation

17:00

Morocco’s Agency for Medicines and Health Products (AMMPS) has ordered the withdrawal of two batches of Cardioaspirine 100 mg following a temperature deviation recorded during their transportation.

The measure, announced on September 16, 2026, applies exclusively to batches BT1CJP2 and BT1CJP3. The agency instructed pharmacies, pharmaceutical wholesalers and other relevant operators to immediately stop distributing, dispensing or using the affected batches, isolate any remaining stock and coordinate its return with Bayer.

The decision is explicitly presented as a precautionary measure. The AMMPS notice does not report a manufacturing defect involving the medicine. It states that the recall was triggered by the temperature deviation observed while the batches were being transported.

Temperature control remains critical for medicines

Maintaining appropriate temperature conditions throughout the pharmaceutical supply chain is an important part of preserving the quality and stability of medicines. A deviation from the required conditions can therefore lead regulators and manufacturers to isolate specific batches while their status is assessed.

In the case of Cardioaspirine 100 mg, the AMMPS said that no product-quality complaint and no pharmacovigilance case linked to the reason for the recall had been reported for the two batches at the time of its notice.

The recall should therefore not be interpreted as applying to the entire Cardioaspirine 100 mg supply in Morocco. The agency specifically identified only the two batch numbers concerned.

What pharmacies and distributors have been asked to do

Pharmacies and pharmaceutical wholesalers have been instructed to identify any remaining units from batches BT1CJP2 and BT1CJP3, immediately suspend their dispensing and distribution, place them in quarantine and arrange their return in coordination with Bayer.

The two batches have also been reported as carrying an expiry date of February 2031. Other Cardioaspirine 100 mg batches are outside the scope of this particular recall.

Cardioaspirine and its active ingredient

Cardioaspirine 100 mg contains acetylsalicylic acid and is marketed in Morocco as a pharmaceutical product from Bayer. The medicine is available in tablet form and belongs to the antiplatelet category.

Medicines containing low-dose acetylsalicylic acid may be prescribed in specific cardiovascular situations to reduce the risk of blood-clot formation and related complications. Their use depends on the patient's medical circumstances and the healthcare professional's advice.

For patients who already have a box at home, the key step is to check the batch number printed on the packaging. If it reads BT1CJP2 or BT1CJP3, patients should contact their pharmacist or healthcare professional for guidance.

Patients taking Cardioaspirine should not stop prescribed treatment on their own. Any decision to replace or discontinue a cardiovascular medicine should be discussed with a healthcare professional.

A targeted pharmaceutical safety measure

The Moroccan recall illustrates how pharmaceutical safety monitoring can extend beyond manufacturing to the conditions under which medicines are transported and handled. In this case, the action is limited to two identified batches following a transport-related temperature deviation, while the AMMPS has not reported quality complaints or related pharmacovigilance cases for those batches.

The immediate priority is the traceability and isolation of the affected stock, followed by its return to Bayer, as authorities and the manufacturer work to ensure that the recalled batches are removed from the distribution chain.